1. A study of MK0140 in diabetic patients with macular edema (0140-001) a study of MK0140 in diabetic patients with macular edema (0140-001). Available from: https://clinicaltrials.gov/ct2/results?term=NCT00692614&Search=Search. Accessed 27-Oct-2021.
2. Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-13504 Sustained Release Implant. BioSpace; 2019.
3. Aerie Pharmaceuticals Initiates Phase 2 Clinical Trials of AR-1105 in Patients with Macular Edema Associated with RVO. Eyewire; 2019.
4. Alhalafi A. Applications of polymers in intraocular drug delivery systems. Oman J Ophthalmol. 2017;10:3–8.
5. Allergan. Allergan receives FDA approval for DURYSTA™ (BIMATOPROST implant) the FIRST and only INTRACAMERAL biodegradable sustained-release implant to lower intraocular pressure in open-angle GLAUCOMA or ocular hypertension patients. 2020.